Regulus Reports Clinical Hold of RG-101
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
Regulus Therapeutics (RGLS) PT Lowered to $9 at FBR
June 28, 2016 1:35 PM EDTFBR Capital analyst Christopher James lowered his price target on Regulus Therapeutics (NASDAQ: RGLS) to $9.00 (from $30.00) following the FDA clinical hold on RG-101 but maintained a Buy rating.
James commented, "We are lowering our price target to $9 on shares of RGLS, following Regulus' announcement yesterday that the FDA has placed its... More
Regulus Therapeutics (RGLS) PT Cut to $13.50 at Chardan Capital Following Clinical Hold
June 28, 2016 7:38 AM EDTChardan Capital Markets analyst Madhu Kumar lowered his price target on Regulus Therapeutics (NASDAQ: RGLS) 33% to $13.50 after the company announced the start of a clinical hold for RG-101 in the treatment of chronic hepatitis C virus (HCV).
Based upon the clinical hold, the firm now lowers their peak risk-adjusted RG-101 sales to $1.2 bn and NPV to $9.24... More
BMO Capital Downgrades Regulus Therapeutics (RGLS) to Market Perform
June 28, 2016 6:39 AM EDTBMO Capital downgraded Regulus Therapeutics (NASDAQ: RGLS) from Outperform to Market Perform with a price target of $4.00 (from $16.00).
Analyst Matthew Luchini commented, "We are downgrading RGLS shares to Market Perform following the announcement that FDA has placed a clinical hold on... More
Regulus Therapeutics (RGLS) Shares Plummet Upon Resumption
June 27, 2016 4:45 PM EDTRegulus Therapeutics (NASDAQ: RGLS) shares resume trading, the stock is down over 50% in after-hours trading.
... MoreRegulus Therapeutics (RGLS) to Resume Trading at 4:40 PM ET
June 27, 2016 4:19 PM EDTRegulus Therapeutics (NASDAQ: RGLS) to Resume Trading at 4:40 PM ET
... More